INVASIVE BREAST CARCINOMA

This study tested a treatment combining enzalutamide (blocks male hormones) and paclitaxel (chemotherapy) given before surgery to women with a specific type of triple-negative breast cancer that has androgen receptors. The goal was to shrink tumors and reduce the amount of breast…

This study tested giving a chemotherapy drug (nab-paclitaxel) and an immunotherapy drug (atezolizumab) before surgery to women with triple-negative breast cancer. The goal was to shrink tumors and reduce the amount of breast tissue that needs to be removed. The trial involved 37 …

This study tested a shorter, higher-dose radiation schedule for people with early-stage breast cancer (stages 0 to IIB). Instead of the usual several weeks, treatment was completed in just 9 days. The goal was to see if this approach could control the cancer while causing fewer s…

This early-phase study tested the safety and best dose of two drugs, abemaciclib and niraparib, given together before surgery for a common type of breast cancer (HR+ HER2-). The goal was to see if this combination could shrink tumors before they are removed. Only 8 people took pa…

This study tested a drug called alisertib, either alone or combined with the hormone therapy fulvestrant, in 96 postmenopausal women with advanced breast cancer that had stopped responding to standard hormone treatments. The goal was to see if these treatments could shrink tumors…

This study tested whether injecting a modified herpes virus (talimogene laherparepvec) directly into breast tumors, alongside standard chemotherapy before surgery, could destroy more cancer cells in people with triple negative breast cancer. The virus is designed to infect and br…

This study looked at whether contrast-enhanced mammography (CEM) can find breast cancers that standard mammograms miss. 89 women who were already diagnosed or highly suspected of having breast cancer got a CEM scan, which uses a dye to make tumors stand out. The goal was to see i…